We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being de... Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease. Show more
Ask ADVFN Intelligence (AI)
- Veligrotug met all primary and secondary endpoints with high statistical significance in THRIVE-2, achieving a week 15 proptosis responder rate (PRR) of 56% (placebo-adjusted PRR of 48%, p <...
- THRIVE-2 global phase 3 clinical trial evaluated efficacy and safety of veligrotug in patients with chronic thyroid eye disease (TED) - - Conference call and webcast to be held Monday, December...
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that...
- Reported positive topline phase 3 data for veligrotug from THRIVE in patients with active thyroid eye disease (TED); on track to report topline data from THRIVE-2 in chronic patients in...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.19 | 6.56370656371 | 18.13 | 19.77 | 17.06 | 2169767 | 19.04760015 | CS |
| 4 | -2.58 | -11.7808219178 | 21.9 | 23.65 | 17.06 | 1800366 | 19.92443527 | CS |
| 12 | -4.965 | -20.4447189623 | 24.285 | 27.2 | 17.06 | 1227874 | 21.37657155 | CS |
| 26 | 6.6 | 51.8867924528 | 12.72 | 27.2 | 11.85 | 1345047 | 19.22375688 | CS |
| 52 | -3.63 | -15.8169934641 | 22.95 | 27.2 | 11.4 | 1153345 | 18.20691974 | CS |
| 156 | -2.2 | -10.2230483271 | 21.52 | 39 | 9.47 | 759137 | 19.83635334 | CS |
| 260 | -2.07 | -9.67741935484 | 21.39 | 39 | 9.47 | 602510 | 19.66508765 | CS |
Monksdream
3 months ago
it_happens
3 months ago
power11
4 months ago
it_happens
4 months ago
power11
4 months ago
it_happens
4 months ago
Monksdream
4 months ago
Apprentice
3 years ago
Apprentice
3 years ago
crudeoil24
3 years ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
